Murli Krishna Pharma Private Ltd. is an innovation-driven pharmaceutical company based in India, focused on developing and manufacturing novel drug delivery systems (NDDS) such as pellets, micro-pellets, and granules using aqueous-based technology. Founded in 2004 by Ms. Satya Vadlamani and Dr. Vijay K. Shastri, MKPPL is committed to offering high-quality, cost-effective drug delivery solutions through advanced R&D, regulatory compliance, and customized formulations.

The company operates a world-class oral solid dosage manufacturing facility, approved by the European Union and WHO for GMP compliance, and a DSIR-approved R&D center. Murli Krishna Pharma caters to over 200 global clients, including 64+ international companies, with a presence across regulated and semi-regulated markets.

As a trusted CDMO partner, MKPPL supports pharmaceutical companies with tailored drug delivery platforms, pre-finished formulations, and intellectual property-driven innovations. The company’s emphasis on solvent-free manufacturing, IPR-backed technologies, and client-focused solutions positions it as a preferred global supplier in the NDDS space.

With a turnover exceeding USD 25 million and consistent 60%+ annual growth, Murli Krishna Pharma continues to deliver excellence, innovation, and compliance in every formulation.